

# Major Products

## Innovative Pharmaceuticals Business

| Brand Name (Generic Name)                               | Efficacy  | Launched | Remarks   |
|---|---|----------|---|
| <b>Japan</b> Daiichi Sankyo Co., Ltd.                   |   |          |   |
| <i>Emgality</i> ( <i>galcanezumab</i> )                 | Prophylaxis of migraine attacks   | 2021     | Humanized CGRP monoclonal antibody. It binds specifically to calcitonin gene-related peptide (CGRP), which is considered to be associated with migraine, and thereby inhibits migraine attacks.   |
| <i>Enhertu</i> ( <i>trastuzumab deruxtecan</i> )        | Anti-cancer agent (HER2 directed antibody drug conjugate)   | 2020     | Antibody-drug conjugate which is composed of a humanized monoclonal antibody specifically targeting HER2, one of the Epidermal Growth Factor Receptor (EGFR) family proteins, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells. |
| <i>Tarlige</i> ( <i>mirogabalin</i> )                   | Pain treatment  | 2019     | An $\alpha 2\delta$ ligand. The pain therapy agent to reduce the neurotransmitter release from nerve terminals.   |
| <i>Canalia</i> ( <i>teneligliptin / canagliflozin</i> ) | Type 2 diabetes mellitus treatment  | 2017     | A first combination drug of the DPP-4 inhibitor <i>teneligliptin</i> and the SGLT2 inhibitor <i>canagliflozin</i> approved in Japan, which demonstrates blood glucose-lowering activity through a complementary pharmacological effect.   |
| <i>Vimpat</i> ( <i>lacosamide</i> )                     | Anti-epileptic agent  | 2016     | Sodium channel blocker. Suppresses the excessive excitation of nerves in the brain, and reduces the occurrence of epileptic seizures.   |
| <i>Efient</i> ( <i>prasugrel</i> )                      | Antiplatelet agent  | 2014     | ADP receptor inhibitor. Inhibits platelet aggregation and reduces the incidence of artery stenosis and occlusion due to thrombosis.   |
| <i>Pralia</i> ( <i>denosumab</i> )                      | Treatment for osteoporosis / inhibitor for rheumatoid arthritis-induced progression of bone erosion | 2013     | Human monoclonal anti-RANKL antibody. Subcutaneous formulation which controls bone resorption and bone destruction by specifically inhibiting RANKL.  |
| <i>Tenelia</i> ( <i>teneligliptin</i> )                 | Type 2 diabetes mellitus treatment  | 2012     | DPP-4 inhibitor. The agent facilitates glucose-dependent insulin release and inhibits glucagon release, thereby demonstrating the blood glucose-lowering activity.  |
| <i>Ranmark</i> ( <i>denosumab</i> )                     | Treatment for bone disorders caused by bone metastases from tumors                                  | 2012     | Human monoclonal anti-RANKL antibody. This controls abnormal bone destruction caused by osteoclasts, and reduces the occurrence of fractures and other skeletal related events (SRE). Approved for the indication of giant cell tumors of bone in 2014 and was designated as an orphan drug.  |
| <i>Lixiana</i> ( <i>edoxaban</i> )                      | Anticoagulant   | 2011     | Orally active Factor Xa inhibitor. Prevents the formation of blood clots by specifically, reversibly and directly inhibiting the enzyme, Factor Xa, a clotting factor in the blood.   |
| <i>Nexium</i> ( <i>esomeprazole</i> )                   | Ulcer treatment   | 2011     | Proton pump inhibitor. This can be used for a wide range of ages, from infants to adults. It suppresses excessive gastric acid secretion.   |
| <i>Memary</i> ( <i>memantine</i> )                      | Alzheimer's disease treatment   | 2011     | N-methyl-D-aspartate (NMDA) receptor antagonist. <i>Memantine</i> slows down progression of dementia symptoms in patients with moderate to severe Alzheimer's disease.  |
| <i>Inavir</i> ( <i>laninamivir</i> )                    | Anti-influenza treatment  | 2010     | Neuraminidase inhibitor that inhibits influenza viral proliferation. Treatment is completed with a single inhaled dosage.   |
| <i>Olmotec</i> ( <i>olmesartan</i> )                    | Antihypertensive agent  | 2004     | Angiotensin II receptor blocker. This suppresses the vasoconstriction effects of angiotensin II, and thereby demonstrates the effect of lowering blood pressure.  |
| <i>Rezaltas</i> ( <i>olmesartan</i> )                   | Antihypertensive agent  | 2010     | A combination drug of two antihypertensive agents: an angiotensin II receptor blocker, <i>olmesartan medoxomil</i> , and a calcium ion antagonist, <i>azelnidipine</i> . This combination demonstrates the effect of decreasing blood pressure through a complementary pharmacological effect.  |
| <i>Cravit</i> ( <i>levofloxacin</i> )                   | Synthetic antibacterial agent   | 1993     | New quinolone antibacterial agent offering strong antibacterial action and a broad antibacterial spectrum.  |
| <i>Mevalotin</i> ( <i>pravastatin</i> )                 | Hypercholesterolemia treatment  | 1989     | HMG-CoA reductase inhibitor (statin) that lowers blood cholesterol levels by inhibiting cholesterol synthesis in the liver.   |
| <i>Loxonin</i> ( <i>loxoprofen</i> )                    | Anti-inflammatory analgesic   | 1986     | Nonsteroidal anti-inflammatory analgesic. Suppresses the production of prostaglandin associated with inflammation, and thereby demonstrates an analgesic effect. Also available as transdermal agents (poultice, gel, tape).  |



Lixiana (Japan)



Tenelia, Canalia (Japan)



Pralia (Japan)



Tarlige (Japan)



Ranmark (Japan)



Efient (Japan)



Enhertu (Japan)



Emgality (Japan)

## Innovative Pharmaceuticals Business

| Brand Name (Generic Name)                                    | Efficacy  | Launched | Remarks   |
|--|---|----------|---|
| <b>US</b> Daiichi Sankyo, Inc.                               |   |          |   |
| <i>Enhertu</i> ( <i>trastuzumab deruxtecan</i> )             | Treatment for malignant tumors (anti-HER2 antibody drug conjugate)  | 2020     | An antibody drug conjugate that combines a fully human monoclonal antibody with a payload drug through a linker. The human monoclonal antibody binds specifically to human epidermal growth factor receptor 2 (HER2), a member of cell growth factor family receptor. The payload is a potent topoisomerase I inhibitor that has high membrane permeability and also kills nearby cancer cells with a bystander effect. |
| <i>Savaysa</i> ( <i>edoxaban</i> )                           | Anticoagulant   | 2015     | Orally active Factor Xa inhibitor. Prevents the formation of blood clots by specifically, reversibly and directly inhibiting the enzyme, Factor Xa, a clotting factor in the blood.   |
| <i>Efient</i> ( <i>prasugrel</i> )                           | Antiplatelet agent  | 2009     | Inhibits platelet aggregation and reduces the incidence of artery stenosis and occlusion  |
| <i>Benicar</i>   |   | 2002     | <i>Benicar: Olmesartan</i>  |
| <i>Benicar HCT</i>   |   | 2003     | <i>Benicar HCT: A combination drug of olmesartan medoxomil and hydrochlorothiazide (diuretic)</i>   |
| <i>Azor</i> ( <i>olmesartan</i> )                            | Antihypertensive agent  | 2007     | <i>Azor: A combination drug of olmesartan medoxomil and amlodipine besylate (calcium channel blocker)</i>   |
| <i>Tribenzor</i>   |   | 2010     | <i>Tribenzor: A triple combination drug of olmesartan medoxomil, hydrochlorothiazide, and amlodipine besylate</i>   |
| <i>Welchol</i> ( <i>colesevelam</i> )                        | Hypercholesterolemia treatment / Type 2 diabetes mellitus treatment | 2000     | Bile acid sequestrant. Marketed as a drug for treatment of hypercholesterolemia. Gained approval also for type 2 diabetes mellitus indication as part of life-cycle management  |
| <b>US</b> American Regent, Inc.                              |   |          |   |
| <i>Injectafer</i> ( <i>ferric carboxymaltose injection</i> ) | Iron deficiency anemia treatment                                    | 2013     | Effective for patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, or who have non-dialysis-dependent chronic kidney disease  |
| <i>Venofer</i> ( <i>iron sucrose injection</i> )             | Iron deficiency anemia treatment                                    | 2000     | Iron replacement product. Effective for treatment of iron deficiency anemia in dialysis patients, etc.  |
| <b>Europe</b> Daiichi Sankyo Europe GmbH                     |   |          |   |
| <i>Enhertu</i> ( <i>trastuzumab deruxtecan</i> )             | Anti-cancer agent (HER2 directed antibody drug conjugate)           | 2021     | Antibody-drug conjugate which is composed of a humanized monoclonal antibody specifically targeting HER2, one of the Epidermal Growth Factor Receptor (EGFR) family proteins, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells.             |
| <i>Lixiana</i> ( <i>edoxaban</i> )                           | Anticoagulant   | 2015     | Orally active Factor Xa inhibitor. Prevents the formation of blood clots by specifically, reversibly and directly inhibiting the enzyme, Factor Xa, a clotting factor in the blood.   |
| <i>Efient</i> ( <i>prasugrel</i> )                           | Antiplatelet agent  | 2009     | Inhibits platelet aggregation and reduces the incidence of artery stenosis and occlusion  |
| <i>Olmotec</i>   |   | 2002     | <i>Olmotec: Olmesartan</i>  |
| <i>Olmotec Plus</i>  |   | 2005     | <i>Olmotec Plus: A combination drug of olmesartan medoxomil and hydrochlorothiazide (diuretic)</i>  |
| <i>Sevikar</i> ( <i>olmesartan</i> )                         | Antihypertensive agent  | 2009     | <i>Sevikar: A combination drug of olmesartan medoxomil and amlodipine besylate (calcium channel blocker)</i>  |
| <i>Sevikar HCT</i>   |   | 2010     | <i>Sevikar HCT: A triple combination drug of olmesartan medoxomil, hydrochlorothiazide, and amlodipine besylate</i>   |

## Generic Business

| Brand Name (Efficacy)                               |
|---|
| <b>Japan</b> Daiichi Sankyo Espha Co., Ltd.         |
| <i>Olmesartan</i> (Antihypertensive agent)          |
| <i>Memantine OD</i> (Alzheimer's disease treatment) |
| <i>Gefitinib</i> (Treatment for malignant tumors)   |
| <i>Bicalutamide</i> (Prostate cancer treatment)     |
| <i>Tamoxifen</i> (Anti-breast cancer agent)         |

## Vaccine Business

| Brand Name  |
|---|
| <b>Japan</b> Daiichi Sankyo Co., Ltd.                   |
| <i>Influenza HA Vaccine</i>                             |
| <i>Live Attenuated Measles-Rubella Combined Vaccine</i> |
| <i>Live Attenuated Mumps Vaccine</i>                    |
| <i>H5N1 Influenza Vaccines</i>                          |

## OTC Related Business

| Brand Name   |
|--|
| <b>Japan</b> Daiichi Sankyo Healthcare Co., Ltd.                               |
| <i>Lulu</i> (Combination cold remedy)  |
| <i>Loxonin S</i> (Antipyretic analgesic / topical anti-inflammatory analgesic) |
| <i>Transino</i> (Melasma improvement / treatment against spots and freckles)   |
| <i>Minon</i> (Skincare)  |
| <i>Breath Labo</i> (Oral care)   |
| <i>Clean Dental</i> (Oral care)  |




Enhertu (US)



Injectafer (US)



Lixiana (Europe)



Memantine OD (Generic Drugs)



Gefitinib (Generic Drugs)



Influenza HA Vaccine (Vaccines)



Lulu (OTC Related Drugs)



Minon series (OTC Related Drugs)